Out of Spec
CMC with a storyline.
Weekly newsletter uncovering what’s really happening in pharmaceutical manufacturing and development. Industry analysis, teardowns, and insights you won’t find anywhere else.
Join 2,500+ biotech professionals
Weekly • Free forever • Unsubscribe anytime
Guides & Resources
S-1 CMC teardowns — what IPO filings reveal about manufacturing readiness
FDA action analysis — warning letters, 483s, and what they mean
CDMO landscape intelligence
Drug program deep dives
Contrarian takes on pharma manufacturing
Practical CMC insights for biotech operators
Who It’s For
Biotech executives and CMC leaders
Investors evaluating biotech manufacturing risk
Pharmaceutical professionals who want the real story
Anyone tired of boring industry newsletters
Issue #47
The CDMO Capacity Crisis
December 18, 2024
Why top-tier CDMOs are booked solid through 2026 and what it means for your program timeline.
Issue #46
S-1 Teardown: Biotech X
December 11, 2024
Reading between the lines of an IPO filing to assess true manufacturing readiness.
Issue #45
Warning Letters Deep Dive
December 4, 2024
Three FDA warning letters this month reveal a troubling pattern in aseptic processing.
Recent Issues